CN104334183A - 基底胰岛素治疗 - Google Patents

基底胰岛素治疗 Download PDF

Info

Publication number
CN104334183A
CN104334183A CN201380028029.4A CN201380028029A CN104334183A CN 104334183 A CN104334183 A CN 104334183A CN 201380028029 A CN201380028029 A CN 201380028029A CN 104334183 A CN104334183 A CN 104334183A
Authority
CN
China
Prior art keywords
patient
insulin
treatment
diabetes
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380028029.4A
Other languages
English (en)
Chinese (zh)
Inventor
P·约翰斯顿
H·格斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN104334183A publication Critical patent/CN104334183A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201380028029.4A 2012-03-28 2013-03-28 基底胰岛素治疗 Pending CN104334183A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261616768P 2012-03-28 2012-03-28
US61/616,768 2012-03-28
US201261619641P 2012-04-03 2012-04-03
US61/619,641 2012-04-03
US201261624598P 2012-04-16 2012-04-16
US61/624,598 2012-04-16
US201261645909P 2012-05-11 2012-05-11
US61/645,909 2012-05-11
US201261701911P 2012-09-17 2012-09-17
US61/701,911 2012-09-17
PCT/EP2013/056661 WO2013144273A1 (en) 2012-03-28 2013-03-28 Basal insulin therapy

Publications (1)

Publication Number Publication Date
CN104334183A true CN104334183A (zh) 2015-02-04

Family

ID=48044781

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380028029.4A Pending CN104334183A (zh) 2012-03-28 2013-03-28 基底胰岛素治疗

Country Status (13)

Country Link
US (1) US20150065421A1 (enExample)
EP (1) EP2830650A1 (enExample)
JP (1) JP2015512908A (enExample)
KR (1) KR20150001757A (enExample)
CN (1) CN104334183A (enExample)
AU (1) AU2013241776B2 (enExample)
CA (1) CA2865823A1 (enExample)
HK (1) HK1201155A1 (enExample)
IN (1) IN2014KN02335A (enExample)
MX (1) MX2014011687A (enExample)
RU (1) RU2014143271A (enExample)
SG (1) SG11201405433XA (enExample)
WO (1) WO2013144273A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110022935A (zh) * 2016-11-28 2019-07-16 诺和诺德股份有限公司 用于心血管病况的德谷胰岛素
CN110099719A (zh) * 2016-11-28 2019-08-06 诺和诺德股份有限公司 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017108943A1 (en) * 2015-12-23 2017-06-29 Sanofi-Aventis Deutschland Gmbh Cardiac metabolic effect of lantus
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
US20190357853A1 (en) * 2018-05-24 2019-11-28 Lizheng Shi Diabetes risk engine and methods thereof for predicting diabetes progression and mortality

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110281793A1 (en) * 2003-01-14 2011-11-17 Aventis Pharmaceuticals Inc. Method For Reducing Cardiovascular Morbidity And Mortality In Prediabetic Patients And Patients With Type 2 Diabetes
WO2011161161A1 (en) * 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110281793A1 (en) * 2003-01-14 2011-11-17 Aventis Pharmaceuticals Inc. Method For Reducing Cardiovascular Morbidity And Mortality In Prediabetic Patients And Patients With Type 2 Diabetes
WO2011161161A1 (en) * 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. A. TAHRANI, ET AL.: "Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service", 《INT J CLIN PRACT》 *
DANIEL J. COX, ET AL.: "Effects of Blood Glucose Rate of Changes on Perceived Mood and Cognitive Symptoms in Insulin-Treated Type 2 Diabetes", 《DIABETES CARE》 *
JULIO ROSENSTOCK, ET AL.: "Basal Insulin Therapy in Type 2 Diabetes 28-week comparison of insulin glargine (HOE 901) and NPH insulin", 《DIABETES CARE》 *
P. WIESLI, ET AL.: "Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes", 《DIABETOLOGIA》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110022935A (zh) * 2016-11-28 2019-07-16 诺和诺德股份有限公司 用于心血管病况的德谷胰岛素
CN110099719A (zh) * 2016-11-28 2019-08-06 诺和诺德股份有限公司 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素

Also Published As

Publication number Publication date
KR20150001757A (ko) 2015-01-06
RU2014143271A (ru) 2016-05-20
SG11201405433XA (en) 2014-10-30
WO2013144273A1 (en) 2013-10-03
AU2013241776A1 (en) 2014-10-16
IN2014KN02335A (enExample) 2015-05-01
EP2830650A1 (en) 2015-02-04
HK1201155A1 (en) 2015-08-28
US20150065421A1 (en) 2015-03-05
JP2015512908A (ja) 2015-04-30
MX2014011687A (es) 2015-05-11
AU2013241776B2 (en) 2017-11-02
CA2865823A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
Lovre et al. Benefits of timely basal insulin control in patients with type 2 diabetes
Rosenstock et al. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target
Janez et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group
Moghissi et al. Hypoglycemia: minimizing its impact in type 2 diabetes
Sweitzer et al. Preoperative care for cataract surgery: the Society for Ambulatory Anesthesia position statement
Oosterom-Eijmael et al. Risk of perioperative discontinuation of SGLT2 inhibitors
Abbatecola et al. Treating diabetes mellitus in older and oldest old patients
AU2013241776B2 (en) Basal insulin therapy
Graveling et al. Does hypoglycaemia cause cardiovascular events?
Papa et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs
CN116867505A (zh) 替西帕肽治疗方法
Golden et al. Management of diabetes during acute stroke and inpatient stroke rehabilitation
Camacho et al. Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus
US20210000792A1 (en) Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
Class et al. Patent application title: BASAL INSULIN THERAPY Inventors: Peter Johnston (Bridgewater, NJ, US) Hertzel Gerstein (Hamilton, CA) Hertzel Gerstein (Hamilton, CA)
Hudson et al. Diabetes in older adults
Biedka et al. Semaglutide in modern medicine: therapeutic opportunities in obesity and the emerging challenge of NAION–a narrative review
P. Toth Effective management of the type 2 diabetes patient with cardiovascular and renal disease: secondary prevention strategies after a myocardial infarction
Wilson Person-centered medication therapy for diabetes in older adults: A practical review
Azeez Present State and Perspectives of Type 2 Diabetes Management
Das et al. Pathophysiology and Clinical Therapeutic Aspects of Diabetes
Cherian et al. Therapeutic implications of diabetes in cardiovascular disease
Valdez et al. Long term evaluation of intensive insulin therapy in patients with type 2 diabetes mellitus
Colwell et al. Glycemic control and heart disease
Jang et al. The Early Detection and Managements of Euglycemic Diabetic Ketoacidosis Based on a Rapid Response System: Two Case Reports

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160811

Address after: Frankfurt, Germany

Applicant after: Sanofi-Aventis Deutschland GmbH

Address before: France

Applicant before: Sai Nuofei

RJ01 Rejection of invention patent application after publication

Application publication date: 20150204

RJ01 Rejection of invention patent application after publication